A lot of money is sloshing around, and medical device start-ups are reaping the benefits.
Medtronic’s quarterly results yesterday might presage a recovery, and some groups are in dire need of one.
And the move will shake up the orthopaedic robotics scene.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
But launch is unlikely before 2024.
Beset with problems from the off, the Lotus Edge aortic valve has finally been discontinued.
The newest player in corporate financing, Intuitive, intends to deploy its fund with surgical precision.